By a News Reporter-Staff News Editor at Biotech Week -- Investigators discuss new findings in Biotechnology. According to news reporting originating from Seattle, Washington, by NewsRx correspondents, research stated, "Hepatocellular carcinoma (HCC) is a devastating malignancy in which imperfect imaging plays a primary role in diagnosis. Glypican-3 (GPC3) is an HCC-specific cell surface proteoglycan overexpressed in most HCCs."
Our news editors obtained a quote from the research from the University of Washington, "This paper presents the use of Zr-89-conjugated monoclonal antibody against GPC3 (Zr-89-alpha GPC3) for intrahepatic tumor localization using PET. Polymerase chain reaction confirmed relative GPC3 expression in cell lines. In vitro binding, in vivo biodistribution, and small-animal PET studies were performed on GPC3-expressing HepG2 and non-GPC3-expressing HLF and RH7777 cells and orthotopic xenografts. Zr-89-alpha GPC3 demonstrated antibody-dependent, antigen-specific tumor binding. HepG2 liver tumors exhibited high peak uptake (836.6 +/- 86.6 percentage injected dose [% ID]/g) compared with background liver (27.5 +/- 1.6 % ID/g). Tumor-to-liver contrast ratio was high and peaked at 32.5. The smallest HepG2 tumor (, 1 mm) showed lower peak uptake (42.5 +/- 6.4 % ID/g) and tumor-to-liver contrast (1.57) but was still clearly visible on PET. Day 7 tissue activity was still substantial in HepG2 tumors (466.4 +/- 87.6 % ID/g) compared with control RH7777 tumors (3.9 +/- 1.3 % ID/g, P, 0.01), indicating antigen specificity by Zr-89-alpha GPC3. HepG2 tumor treated with unlabeled aGPC3 or heat-denatured Zr-89-alpha GPC3 demonstrated tumor activity (2.1 % ID/g) comparable to that of control xenografts, confirming antibody dependency. This study demonstrated the feasibility of using Zr-89-alpha GPC3 to image HCC in the liver, as well as the qualitative determination of GPC3 expression via small-animal PET."
According to the news editors, the research concluded: "The ability to clarify the identity of small liver lesions with an HCC-specific PET probe would provide clinicians with vital information that could significantly alter patient management, warranting further investigation for clinical translation."
For more information on this research see: Glypican-3-Targeted Zr-89 PET Imaging of Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2014;55(5):799-804. Journal of Nuclear Medicine can be contacted at: Soc Nuclear Medicine Inc, 1850 Samuel Morse Dr, Reston, VA 20190-5316, USA (see also Biotechnology).
The news editors report that additional information may be obtained by contacting J.G. Sham, University of Washington, Dept. of Mat Sci & Engn, Seattle, WA 98195, United States. Additional authors for this research include F.M. Kievit, J.R. Grierson, R.S. Miyaoka, M.M. Yeh, M.Q. Zhang, R.S. Yeung, S. Minoshima and J.O. Park.
Keywords for this news article include: Antibodies, Biotechnology, Seattle, Washington, Immunology, United States, Blood Proteins, Immunoglobulins, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC